Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pneumovax 23 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Pneumovax 23™ | BIOLOGICAL | Single dose intramuscular injection |
Inclusion criteria * Subjects who the investigator believes will comply with the requirements of the protocol. * A male or female \>= 65 years at the time of the first vaccination. * Written informed consent obtained from the subject. Exclusion criteria * Use of any investigational or non-registe...
Pneumovax 23 is a vaccine used for Streptococcus pneumoniae, the bacterium that causes pneumococcal disease. It is being studied in an elderly population aged 65 years and older to evaluate the response rate to the licensed vaccine. The vaccine is intended to help protect against pneumococcal infections.
Pneumovax 23 is developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. GSK is conducting clinical development of the vaccine for Streptococcus pneumoniae.
Pneumovax 23 is in Phase 2 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. The Phase 2 trial has been completed, and the vaccine is still in clinical development.
Pneumovax 23 has one completed clinical trial, NCT00307008, titled 'Study to Evaluate the Response Rate to the Licensed Pneumovax 23™ in Elderly Population.' This Phase 2 trial enrolled 1,198 participants in Sweden, all aged 65 years and older, and was a healthy volunteer study.
No, Pneumovax 23 is a vaccine, not a monoclonal antibody. It is designed to elicit an immune response against Streptococcus pneumoniae. The modality listed for the drug is monoclonal antibody, but the product is a vaccine used for immunization.